Last reviewed · How we verify
RLD2209-1
RLD2209-1 is a small molecule that targets the SGLT2 receptor.
RLD2209-1 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | RLD2209-1 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
RLD2209-1 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism of action is similar to other SGLT2 inhibitors, which have been shown to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RLD2209-1 CI brief — competitive landscape report
- RLD2209-1 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI